Replies to post #176569 on Biotech Values

[DewDiligence]

…you feel that Gilead would sit on the sidelines while 50% of their market disappears? I don't think so.

Two comments: i) the 50% number is not mine; and ii) the all-oral GT1 market we’re talking about does not belong to GILD; rather, GILD will be entering this market around the same time as ABBV/ENTA.

[zipjet]

And you feel that Gilead would sit on the sidelines while 50% of their market disappears? I don't think so.

Nor do I.

The question is given the elasticity of demand (which the survey now gives some data), what discount to Sovaldi will maximize profitability for ABBV?

My guess is about 15%.

Should be interesting to see how it comes out.